Moffett B S, Haworth T E, Wang Y, Afonso N, Checchia P A
Department of Pharmacy, Texas Children's Hospital, Houston, TX, USA.
Texas Children's Hospital, Houston, TX, USA.
J Clin Pharm Ther. 2017 Aug;42(4):433-437. doi: 10.1111/jcpt.12525. Epub 2017 Apr 5.
Spironolactone is used in paediatric patients with heart disease, yet few data are available regarding the impact on potassium supplementation.
We sought to determine the effect of spironolactone on potassium supplementation in paediatric cardiac intensive care patients.
A retrospective, propensity matched cohort study was designed. Patients were included in the study if they received furosemide therapy in the cardiac intensive care unit at our institution. Patients who received spironolactone were matched to patients who did not receive spironolactone. Data collection included patient demographics, diuretic data, potassium monitoring, and total milliequivalents of potassium administered during the cardiac intensive care unit stay.
A total of 448 patients met study criteria median age 0.43 (IQR 0.06-3.52) years, 58.9% male. Intensive care unit length of stay was 7 (IQR 3-17) days, cardiovascular surgery occurred in 90.4%. Patients had a mean 4.6±2.6 potassium concentrations assessed per day (29.5%±19.4%<3.5 mmol/L, and 2.9%±6.5%>5.5 mmol/L). Patients received a median of 5.1 mEq/kg (0-323.4 mEq/kg) of potassium. Spironolactone (n=224) was administered for 2 days (IQR 1-4) at mean dose of 0.64±0.54 mg kg d . Median total mEq/kg of potassium administered did not differ between groups (4.6 mEq/kg (IQR 0.66-16.8) vs 6.5 mEq/kg (IQR 1.3-18.3 mEq/kg), P=.13). Potassium laboratory values did not differ in hypokalemia (27.8%±19.1% vs 31.2%±19.5%, P=.06) or hyperkalemia (2.8%±5.4% vs 3.2%±7.5%, P=.49) between groups.
Spironolactone supplementation did not reduce the need for potassium supplementation in paediatric cardiac intensive care patients.
The routine use of spironolactone in the paediatric cardiac intensive care population may not be more efficacious than potassium supplementation for maintenance of serum potassium concentrations.
螺内酯用于患有心脏病的儿科患者,但关于其对补钾影响的数据很少。
我们试图确定螺内酯对儿科心脏重症监护患者补钾的影响。
设计了一项回顾性、倾向匹配队列研究。如果患者在我们机构的心脏重症监护病房接受速尿治疗,则纳入研究。接受螺内酯治疗的患者与未接受螺内酯治疗的患者进行匹配。数据收集包括患者人口统计学、利尿剂数据、钾监测以及在心脏重症监护病房住院期间给予的钾的总毫当量。
共有448名患者符合研究标准,中位年龄0.43(四分位间距0.06 - 3.52)岁,58.9%为男性。重症监护病房住院时间为7(四分位间距3 - 17)天,90.4%进行了心血管手术。患者每天平均评估4.6±2.6次钾浓度(29.5%±19.4%<3.5 mmol/L,2.9%±6.5%>5.5 mmol/L)。患者接受的钾中位数为5.1 mEq/kg(0 - 323.4 mEq/kg)。给予螺内酯(n = 224)2天(四分位间距1 - 4),平均剂量为0.64±0.54 mg·kg⁻¹·d⁻¹。两组间给予的钾的总毫当量/千克中位数无差异(4.6 mEq/kg(四分位间距0.66 - 16.8)对6.5 mEq/kg(四分位间距1.3 - 18.3 mEq/kg),P = 0.13)。两组间低钾血症(27.8%±19.1%对31.2%±19.5%,P = 0.06)或高钾血症(2.8%±5.4%对3.2%±7.5%,P = 0.49)时的钾实验室值无差异。
补充螺内酯并未减少儿科心脏重症监护患者的补钾需求。
在儿科心脏重症监护人群中常规使用螺内酯在维持血清钾浓度方面可能并不比补钾更有效。